AstraZeneca Teams Up With Venter, Sanger To Mine Genomic Riches
This article was originally published in Scrip
Executive Summary
AstraZeneca has entered into a series of early research collaborations in a bid to integrate genomics into the foundations of its entire drug discovery and development infrastructure.